The FDA approved Johnson & Johnson's Invokana, or canagliflozin, as an adjunct therapy to diet and exercise in adults with type 2 diabetes. The drug, from J&J unit Janssen Pharmaceuticals, is the first sodium-glucose co-transporter 2 inhibitor approved for diabetes. The approval was based on data from nine late-stage studies that showed improvements in hemoglobin A1c levels and fasting blood sugar levels.
J&J's first-in-class Invokana gets FDA OK for type 2 diabetes
SmartBrief Job Listings for Health Care
|Clinical Trials Agreements Specialist (209955)||
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
|Catheter Engineer Manager||
ASAHI INTECC, Orange County CA R&D Center
|Santa Ana, CA|
|Neurovascular Intervention Product Sales Rep, North East||
|Multiple Locations, SL_Multiple Locations|
|Senior Manager, Compliance||
|Director, Office of Device Evaluation||
FDA, Center for Devices and Radiological Health
|Silver Spring, MD|